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OBJECTIVE
We tested the ability of a type 1 diabetes (T1D) genetic risk score (GRS) to predict
progression of islet autoimmunity and T1D in at-risk individuals.
RESEARCH DESIGN AND METHODS
We studied the 1,244 TrialNet Pathway to Prevention study participants (T1D
patients’ relatives without diabetes and with one or more positive autoantibodies)
who were genotyped with Illumina ImmunoChip (median [range] age at initial
autoantibody determination 11.1 years [1.2–51.8], 48% male, 80.5% non-Hispanic
white, median follow-up 5.4 years). Of 291 participants with a single positive
autoantibody at screening, 157 converted to multiple autoantibody positivity and
55 developed diabetes. Of 953 participants with multiple positive autoantibodies
at screening, 419 developed diabetes. We calculated the T1D GRS from 30 T1D-
associated single nucleotide polymorphisms.We usedmultivariable Cox regression
models, time-dependent receiver operating characteristic curves, and area under
the curve (AUC) measures to evaluate prognostic utility of T1D GRS, age, sex,
Diabetes Prevention Trial–Type 1 (DPT-1) Risk Score, positive autoantibody num-
ber or type, HLA DR3/DR4-DQ8 status, and race/ethnicity. We used recursive par-
titioning analyses to identify cut points in continuous variables.
RESULTS
Higher T1D GRS significantly increased the rate of progression to T1D adjusting for
DPT-1 Risk Score, age, number of positive autoantibodies, sex, and ethnicity (hazard
ratio [HR] 1.29 for a 0.05 increase, 95% CI 1.06–1.6; P = 0.011). Progression to T1D
was best predicted by a combined model with GRS, number of positive autoanti-
bodies, DPT-1 Risk Score, and age (7-year time-integrated AUC = 0.79, 5-year AUC =
0.73). Higher GRS was significantly associated with increased progression rate from
single to multiple positive autoantibodies after adjusting for age, autoantibody
type, ethnicity, and sex (HR 2.27 for GRS >0.295, 95% CI 1.47–3.51; P = 0.0002).
CONCLUSIONS
The T1D GRS independently predicts progression to T1D and improves prediction
along T1D stages in autoantibody-positive relatives.
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Early identification of individuals at risk
for type 1 diabetes (T1D) allows study of
the biology of the preclinical stages of
T1D and inclusion of those at highest T1D
risk in monitoring and prevention trials.
Current prediction models for T1D use
immunologic andmetabolicmarkers, but
these markers change during disease
progression and reflect advanced stages
in the autoimmune process (1–7), whereas
genetic predictors are time-independent
and may be assessed only once at study
entry. T1D has a significant heritable risk
as evidenced by studies of monozygotic
twins that demonstrated rates of disease
concordance .50%, higher with youn-
ger age at diagnosis of the index twin
(8,9). Approximately 50% of this herita-
bility is attributable to the HLA region
(10),with another.50 locimaking smaller
contributions to disease risk (reviewed in
previous studies [11–13]). Recently, Oram
et al. (14) developed and validated a T1D
genetic risk score (GRS) that incorporates
HLA and non-HLA T1D-associated single
nucleotide polymorphisms (SNPs) and was
discriminative of T1D from type 2 diabe-
tes, monogenic diabetes, and controls (15).
In this study, we tested the prognostic
utility of the T1D GRS for differentiating
rates of progression of islet autoimmu-
nity and development of clinical T1D in
autoantibody-positive relatives of individ-
uals with T1D.
RESEARCH DESIGN AND METHODS
Participants
Type 1 Diabetes TrialNet is a National
InstitutesofHealth–funded international
network that aims to prevent T1D (16).
TrialNet Pathway to Prevention (PTP) is
an observational study that prospec-
tively follows at-risk first- or second-
degree relatives of patients with T1D for
development of islet autoimmunity and
clinical T1D (17). This study included
TrialNet PTP participants who had one
or more positive, persistently detectable
islet autoantibodies and had been geno-
typed using the Illumina ImmunoChip
(n = 1,244). Study participants gave in-
formed consent and the study was ap-
proved by ethics committees at each site.
Procedures
Participants were initially screened for
autoantibodies to glutamic acid decar-
boxylase (GAD65), insulin (microinsulin
antibody assay [mIAA]), and insulinoma-
associated antigen 2 (IA-2A). If any of
these was positive, autoantibodies to
zinc transporter 8 (ZnT8) and islet cell
antibodies (ICA)were tested. Participants
were monitored with autoantibody test-
ing, hemoglobin A1c (HbA1c), and oral
glucose tolerance test at 6- or 12-month
intervals depending on estimated risk
(18). T1D was diagnosed in participants
with 1) symptomatic hyperglycemia,
defined as fasting plasma glucose $7.0
mmol/L, 2-h plasma glucose after 75 g
oral glucose $11.1 mmol/L, a ran-
dom plasma glucose $11.1 mmol/L, or
an HbA1c $6.5%; or 2) asymptomatic
hyperglycemia documented on two sep-
arate occasions. Islet-autoantibody (17)
and C-peptide (19) assays have been
previously described. HLA genotyping
was performed as previously described
(20). Illumina ImmunoChip genotyping
was performed at the Center for Public
Health Genomics, University of Virginia.
The Diabetes Prevention Trial–Type 1
(DPT-1) Risk Score is a diabetes risk score
derived from ICA-positive individuals and
validated in TrialNet that combines BMI,
age, glucose, and C-peptide (2,21). We
stratified our analysis by a metabolic
DPT-1 Risk Score of #7 or .7 based on
previous work (22).
T1D GRS
The T1D GRS was calculated from 30 var-
iants known to be associated with T1D
(Supplementary Table 2), ranked and
weighted by published odds ratios as
previously described (14). We drew
odds ratios for each SNP from the largest
available meta-analysis study that used
T1Dbase (http://t1dbase.org/). Twenty-
nine of these variants were directly
genotyped, whereas rs11755527 was
imputed using IMPUTE2 (r2 = 0.99997).
rs2187668 and rs7454108 were used
to determine HLA DR haplotype (23).
The T1D GRS threshold that was pre-
viously shown to optimally discrimi-
nate T1D from type 2 diabetes was
0.280 (14). T1D GRS percentiles in a
reference T1D population (24) are
provided to allow comparisons be-
tween different genetic scores. The
same methods were used to calcu-
late a 10-SNP score using the top 10
T1D-associated SNPs (Supplementary
Table 2), which account for most of
the genetic risk. We assessed the pre-
dictive power of both the 10-SNP and
30-SNP scores.
Statistical Analyses
We used summary statistics and graph-
ical analyses to assess the distributions
and characteristics of the clinical and
metabolic measures as well as the T1D
GRS, overall and by subgroup. Comparisons
between subgroups were made using pri-
marily nonparametric approaches, e.g.,
Wilcoxon rank sum or Kruskal-Wallis
test and the x2 or Fisher exact test, as
appropriate.
Kaplan-Meier methods were used to
evaluate the time-to-event distributions
for time to progression to T1D and time
from single to multiple autoantibody
positivity overall and in subgroups (see
Supplementary Table 3 for definitions).
Cox proportional hazards models were
used to test the prognostic influence of
these measures on these outcomes in
univariate and multivariable settings. Mod-
els were adjusted for age, sex, and race/
ethnicity. For models of time to conver-
sion from single to multiple autoanti-
bodies, we also adjusted for autoantibody
type (i.e., GAD65, insulin, or IA-2A). For
time-to-T1D models, we additionally ad-
justed for DPT-1 Risk Score and the
number of positive autoantibodies pres-
ent at screening. T1DGRS, age, andDPT-1
Risk Score were each evaluated as con-
tinuous and dichotomized factors. We
assessed whether T1D GRS added pre-
dictive power independently over HLA
DR3/DR4-DQ8 status by including DR3/
DR4-DQ8 in initial multivariate anal-
yses; the HLA DR3/DR4-DQ8 variable
was then removed from the final models
because the overlap between the two
variables (i.e., HLA DR3/DR4-DQ8 is in-
cluded in the T1D GRS) caused collinearity.
Recursive partitioning analyses (risk-
stratification method based on classifi-
cation and regression trees) were used
to identify variables and associated cut
points that best differentiated outcome-
specific risk (rpart package in R) (25).
To obtain stable hazard ratio (HR) esti-
mates reflecting meaningful unit changes
in the continuous 30-SNP T1D GRS mea-
sure, we multiplied this measure by a
constant (3 20) when included as a con-
tinuous factor in models. All reported
HRs for continuous T1D GRS measures
reflect this multiplier and reflect HRs as-
sociated with an increase of 0.05 in the
T1D GRS.
The predictive accuracy of models for
time to progression to multiple auto-
antibodies and to T1D was evaluated for
1888 Genetic Risk Score in Type 1 Diabetes Prediction Diabetes Care Volume 41, September 2018
T1D GRS (or HLA), islet autoantibody num-
ber, age, and DPT-1 Risk Score using time-
dependent area under the curve (AUC)
analyses (survAUC in R). Time-integrated
AUC measures were calculated for each
model in addition to year-specific AUCs on
subjects with complete data for the mul-
tivariable models, consistent with stan-
dard AUC goodness-of-fit measures. In
addition, to evaluate if GRS added more
to our prognostic models than HLA, we
directly compared the GRS versus HLA
models as well as comparing them com-
bined with clinical factors (DPT-1 Risk
Score, age, autoantibody number). Time-
integrated AUC estimates were limited to
7 years given that the third quartile for
follow-up in event-free participants in the
overall cohort was just over 7 years. Pre-
dictive accuracy between models was
compared at major time points and
reflects comparisons of estimated 5-year
AUCs unless stated otherwise (timeROC
package in R).
RESULTS
Characteristics of TrialNet participants
in this study (n = 1,244) are presented in
Supplementary Table 4. The median age
at autoantibody determination was 11.1
years (range 1.2–51.8), 48% were male,
81% non-Hispanic white, and 90% first-
degree relatives of a patient with T1D.
The estimated median follow-up was 5.4
years [95% CI 5.0–5.8]. Of the 291 par-
ticipants positive for a single antibody,
157 progressed to multiple autoantibody
positivity and 55 developed T1D. Of the
953 participants who had multiple anti-
bodies when initially screened, 419 de-
veloped T1D.
Overall, the 30-SNP T1D GRS ranged
from 0.138 to 0.341 (median = 0.272,
corresponding to the 38th–39th percen-
tiles in the reference T1D population
[24]). The median T1D GRS for single
andmultiple autoantibody–positive sub-
jects were 0.266 (30th percentile, range
0.138–0.341) and 0.274 (41st percentile,
range 0.169–0.328), respectively.
T1D GRS Is an Independent Predictor
of Clinical T1D in Islet Autoantibody–
Positive Relatives
The T1D GRS was a significant predictor
of risk and rate of progression to T1D in
continuous univariate analysis (HR 1.7,
95% CI 1.43–2.0; P , 0.0001) as well as
after adjustment for other risk factors
(Supplementary Table 5). Of note, with
inclusion of the T1D GRS in themultivari-
able model, HLA DR3/DR4-DQ8 was no
longer significant (HR 1.06, 95% CI 0.79–
1.41;P = 0.71 [data not shown]). The best
predictive model of progression to T1D,
with a 7-year time-integrated AUC of
0.794, included GRS, the metabolic DPT-1
Risk Score, age at autoantibody determi-
nation, and number of positive autoanti-
bodies (Supplementary Table 5). The GRS
remained a significant predictor in this
model (HR 1.29, 95% CI 1.06–1.56; P =
0.009). Since we observed a significant
interaction between T1D GRS and DPT-1
Risk Score (P = 0.001), as well as be-
tween GRS and autoantibody number (P =
0.001), next we also analyzed models of
progression to T1D stratified by these
features.
Interaction and stratified analyses
revealed that GRS is best able to fur-
ther differentiate T1D risk in those par-
ticipants with a baseline metabolic DPT-1
Risk Score #7.0 (n = 716, which repre-
sents 63% of 1,136 participants with DPT-
1 Risk Score data available at baseline)
(HR 1.66, 95% CI 1.18–2.34; P = 0.003)
even after adjusting for age, autoanti-
body number, sex, ethnicity, and DPT-1
Risk Score (Supplementary Table 5B). Al-
though those with a DPT-1 Risk Score .7
had a higher T1D GRS than those with
DPT-1 Risk Score #7 (0.274 [SD 0.026]
vs. 0.268 [0.028]; P = 0.002), the GRS did
not further stratify the risk of T1D in
participants who had already developed
metabolic abnormalities, as reflected by a
DPT-1 Risk Score .7.0 (HR 1.07, 95% CI
0.81–1.41; P = 0.64).
Since ICA and GAD65 autoantibodies
may overlap (26), we performed sensi-
tivity analyseswith the 167 (out of 1,244)
subjects who were only positive for ICA
and GAD65 in this cohort and observed
that their classificationaspositive forone
versus two autoantibodies yielded sim-
ilar results and consistent estimates.
Multivariable recursive partitioning
models identified variable cut points
and five risk clusters (Fig. 1 and Sup-
plementary Fig. 1). The optimal cut point
for GRS in relation to time to progression
to T1D was 0.250. DPT-1 Risk Score .7
identified the highest risk group, while
in those with DPT-1 Risk Score#7 the risk
of T1D could be further stratified accord-
ing to autoantibody number and T1D GRS.
To assess the improvement of T1D pre-
diction when T1D GRS was included with
established predictors, we calculated
time-dependent receiver operating char-
acteristic (ROC) curves integrated across
all time points (iAUC) and standard ROC
curves for the2-and5-year timepoint. For
the overall at-risk cohort with complete
data on these factors (n = 1,106, 415
events), the iAUCs were 0.57 for T1D
GRS, 0.53 for HLA, 0.59 for autoantibody
number, 0.59 for age, and 0.77 for DPT-1
Risk Score. The iAUC for the final com-
posite risk model (i.e., T1D GRS, metabolic
DPT-1 Risk Score, age, and autoantibody
number) was 0.79. Given that we iden-
tified that GRS has the most prognostic
utility in participants with DPT-1 Risk
Score #7, we also evaluated the time-
dependent ROC and AUC measures in
those with complete data on these fac-
tors (n = 696, 132 T1D events). In this
subset, we found similar patterns of iAUC
for these factors. We observed that the
model with GRS combined with the
“clinical” variables (i.e., DPT-1 Risk Score,
age, and autoantibody number) had sig-
nificantly better prediction accuracy than
the model with HLA combined with the
clinical variables, although this was sig-
nificant at earlier time points (i.e., ROC
and AUC estimates for up to 3 years). For
example, the 2-year AUC for the clinical +
HLA model was 0.78 versus 0.82 for the
clinical +GRSmodel (P,0.0001) (Fig. 2).
Similarly, we observed that, in the par-
ticipants with lower metabolic risk, the
T1D prediction model that combined
GRS with the clinical variables DPT-1
Risk Score, age, and autoantibody num-
ber performed significantly better than
HLA DR3/DR4-DQ8 in addition to the
clinical variables (iAUC 0.60 vs. 0.53; P =
0.007).
T1D GRS Is an Independent Predictor
of Progression From Multiple Islet
Autoantibody Positivity to T1D
There were 953 participants who were
identified as having multiple autoanti-
body positivity at screening and 157
additional participants who developed
multiple positive autoantibodies dur-
ing follow-up, for a total of 1,110 mul-
tiple autoantibody–positive participants
in our cohort. After adjusting for age and
DPT-1 Risk Score, the T1D GRS was a
significant independent prognostic fac-
tor for time to progression to T1D as a
continuous (P = 0.015) and as a dichot-
omized variable (cut point = 0.250, P =
0.017) (Supplementary Table 6). Among
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multiple autoantibody–positive partici-
pants with lower metabolic DPT-1 Risk
Score, high T1D GRS was a significant
factor in multivariable analysis (T1D
GRS$0.250, HR 2.07, 95% CI 1.21–3.55; P =
0.008) (Supplementary Table 6B). Five-
year T1D-free rate estimates were 89%
for those with a low T1D GRS (,0.250)
versus 77% in participants with high
T1D GRS ($0.250). The risk of progress-
ing from multiple islet autoantibody
positivity to T1D could be stratified by the
composite grouping of DPT-1 Risk Score,
age, and T1D GRS (Fig. 3). Time-to-event
ROC and AUC analyses demonstrated
that the addition of GRS to the model
with age and DPT-1 Risk Score improved
the prediction model for T1D in a similar
manner to that seen in all autoantibody-
positive participants with DPT-1 Risk
Score #7 (2-year AUC: clinical + HLA
0.68 vs. clinical + GRS 0.73; P , 0.0001).
Interestingly, the GRS improved the pre-
diction afforded by HLA DR3/DR4-DQ8
alone (iAUC: 0.65 vs. 0.56, respectively;
P = 0.006).
T1D GRS Is an Independent Predictor
of Progression of Islet Autoimmunity
In our cohort, 157 of the 291 single
autoantibody–positive participants pro-
gressed to multiple islet autoantibody
positivity. Elevated T1D GRS was associ-
ated with progression from single to mul-
tiple autoantibody positivity, where an
increase of 0.050 (e.g., from 0.225 to
0.275) significantly increased risk by 50%
(HR 1.49, 95% CI 1.1–2.05; P = 0.015)
after adjustment for age, sex, ethnicity,
and autoantibody type (Supplementary
Table 7).
Recursive partitioning identified 0.295
(69th–70th percentiles) as the optimal
cut point to discriminate individuals
with the highest rate of progression from
single to multiple autoantibody positiv-
ity. Single autoantibody–positive partic-
ipants whose T1D GRS exceeded 0.295
had more than two times higher risk of
autoantibody progression (HR 2.27, 95%
CI 1.47–3.51; P = 0.0002), even adjust-
ing for age, autoantibody type, sex, and
ethnicity.
We observed a potential interaction
between T1D GRS and age at first auto-
antibody determination (P = 0.052). In
participants ,35 years (n = 229), after
adjusting for age, sex, ethnicity, and
autoantibody type, T1D GRS was a sig-
nificant predictor of progression to mul-
tiple autoantibody positivity, both as a
continuous (HR 1.65, 95% CI 1.15–2.37;
P = 0.0065) and dichotomous variable,
with a cut point of 0.295 (HR 2.57, 95% CI
1.6–4.13; P = 0.0001) but also 0.250
(HR 1.68, 95%CI 1.07–2.64; P = 0.023). On
the other hand, in older participants
($35 years of age when classified as
single autoantibody positive), whowere
at much less risk of T1D overall, the T1D
GRS did not significantly inform the risk
and prognosis for progression to mul-
tiple autoantibody positivity after ad-
justing for autoantibody type and sex
(age was not significant and thus was
excluded from the model), although the
numbers were relatively smaller (n = 62;
HR 0.86, 95% CI 0.25–2.96; P = 0.81)
(Fig. 4).
In time-dependent ROC analysis, the
T1D GRS alone delivered an iAUC of 0.55
compared with 0.53, 0.52, and 0.53 for
age, autoantibody type, and HLA DR3/
DR4-DQ8 heterozygosity, respectively.
The iAUC of a multivariable model that
combined age, autoantibody type, and
T1D GRS was 0.58.
A Reduced 10-SNP T1D GRS Performed
Similarly to the T1D GRS in Predicting
Islet Autoimmunity Progression
and T1D
We evaluated the performance of a T1D
GRS based on the top 10 SNPs (14) (T1D
GRS-10), using the same analytic ap-
proach as for the 30-SNP measure. In
multivariable analysis, the T1D GRS-10
predicted progression to T1D in all sub-
jects (HR 1.16 for each increase of 0.10 in
score, 95%CI 1.03–1.31; P = 0.014) and in
the subgroup of multiple autoantibody–
positive subjects (HR 1.15, 95% CI 1.02–
1.30; P = 0.024). Similarly to the 30-SNP
score, the 10-SNP GRS was only a signif-
icant factor in those with the metabolic
DPT-1 Risk Score ,7 (P = 0.0026). T1D
GRS-10 also predicted progression from
single to multiple autoantibody positiv-
ity after adjusting for age, sex, ethnicity,
Figure 1—Time to T1D in patients’ relatives whowere initially without diabetes and islet autoantibody–
positive (Ab+), by DPT-1 Risk Score (#7 vs. .7), number of positive autoantibodies (i.e., single vs.
multiple autoantibody positivity), and T1DGRS (,0.250 vs.$0.250) (P, 0.0001).While the T1DGRS
did not further increase the predictive ability in the group with DPT-1 Risk Score.7, which already
had high risk of T1D, it was able to stratify risk in individuals with DPT-1 Risk Score ,7, with either
a single positive autoantibody or multiple positive autoantibodies. DPTRS, DPT-1 Risk Score.
Figure 2—Comparison of 2-year AUC for
models to predict progression to T1D in
participants with DPT-1 Risk Scores #7.
The clinical model (i.e., DPT-1 Risk Score,
age, and islet autoantibody number) in ad-
dition to HLA had a 2-year AUC of 0.78,
compared with 0.82 for the clinical model
in addition to GRS (P , 0.0001).
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and autoantibody type (HR 1.26 for a 0.1
increase in T1D GRS-10, 95% CI 1.03–
1.55; P = 0.026). The overall predictive
power of T1D GRS-10 was similar to that
of the 30-SNP GRS (iAUC = 0.575).
CONCLUSIONS
We studied 1,244 relatives of patients
with T1D who initially did not have
diabetes and were islet autoantibody
positive and demonstrated that the
T1D GRS is an independent predictor
of progression of islet autoimmunity
and development of clinical T1D. The
T1D GRS improved current prediction
models by stratifying risk among in-
dividuals who were either single or
multiple autoantibody positive. We
demonstrated that the combined mod-
eling of the T1D GRS, which includes HLA
and non-HLA factors, added to autoan-
tibody and metabolic data offers better
prediction of T1D in at-risk relatives. This
approach could increase our ability to
predict T1D in relatives of patients, as
well as to screen and select participants
for natural history studies and interven-
tion trials.
This study adds to the recent expand-
ing literature on the applicability of ge-
netic information in the prediction of
T1D. The T1D GRS used in the current
study was originally developed and val-
idated to distinguish T1D and type 2
diabetes in the Wellcome Trust Case
Control Consortium (WTCCC) (n = 3,887)
and in a cohort defined by insulin in-
sufficiency (14). The score was also able
to discriminate T1D and maturity-onset
diabetes of the young and, in neonates,
monogenic neonatal diabetes (15). Our
present findings extend the use of the
T1D GRS to prediction of T1D in relatives
at risk. There have been previous at-
tempts to develop genetic scores that
integrate genetic information to improve
the prediction of T1D (reviewed in a
recent study [27]). In particular, it was
shown that the combination of HLA and
non-HLA genetic factors increases the
power of the T1D predictive model
(28–31). Winkler et al. (29) developed
a genetic score using logistic regression
and Bayesian feature selection of the
Type 1 Diabetes Genetics Consortium
(T1DGC) to define a set of 10 SNPs,
including HLA, that identified risk of
T1D in first-degree relatives from the
BABYDIAB study. Our score, although
generated from a log-additive model,
contains very similar genetic informa-
tion, so it is not surprising that the results
are consistent. A key additional benefit
of our T1D GRS is the inclusion of SNPs
tagging other significant HLA risk al-
leles, e.g., HLA DRB1*15, DRB1*57, and
A24. Specifically, DRB1*15:01 (linked to
DQB1*06:02) is common in Caucasians
and confers strong genetic protection
against T1D (20). A score generated by
merging the Winkler and colleagues
(29,30) and Oram et al. (14) scores has
recently been proposed to identify new-
borns from the general population who
will develop islet autoimmunity and
T1D. In their study, Bonifacio et al. (32)
demonstrated that even in a subset of
individuals with high-risk HLA genotypes
Figure 3—Time to T1D in multiple islet autoantibody–positive (Ab+) relatives, by DPT-1 Risk Score
(#7 vs. .7), age (,10 vs. $10 years), and T1D GRS (,0.250 vs. $0.250) (P = 0.0001). While
the T1DGRSdidnot further increase thepredictive ability in participantswithDPT-1Risk Score.7,
it did stratify risk in individuals with DPT-1 Risk Score,7, aged,10 years or$10 years. DPTRS,
DPT-1 Risk Score.
Figure 4—Time from single to multiple islet autoantibody positivity (Ab+) in relatives of patients,
by age (,35 vs.$35 years) and T1D GRS group (,0.295 vs.$0.295) (P = 0.0001). While the T1D
GRS did not further increase the predictive ability in participants aged $35 years, it was able
to stratify risk in individuals aged ,35 years.
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from The Environmental Determinants
of Diabetes in the Young (TEDDY) study,
a T1D genetic score predicted develop-
ment of autoantibodies. Although dif-
ferent characteristics in each cohort
(e.g., age, background risk of T1D, pro-
portion of individuals with a relative
with T1D) may require adaptations of
the T1D GRS, the concept of combining
genetic information into a single factor
will greatly improve its utility for pre-
diction and trial design. By virtue of
being a number, the T1D GRS facilitates
incorporation of complex genetic infor-
mation into prediction models. Impor-
tantly, selecting appropriate cut points
will optimize the use of the T1D GRS for
different goals.
The T1D GRS significantly added pre-
dictive power to the current variables
used to stratify T1D risk in the TrialNet
PTPstudy. Themeasurementofautoanti-
bodies and differences in risk associated
with autoantibody positivity are well de-
scribed (33), as are the impact of age
and metabolic data (34–36). The fact
that the T1D GRS was not a predictor
in those with DPT-1 Risk Score.7 dem-
onstrates that, when metabolic abnor-
malities develop,measures that evaluate
these directly become most predictive
and, consequently, the role of genetics in
risk assessment diminishes. However, the
majority of individuals entering TrialNet
PTP have a low DPT-1 Risk Score; in this
group, the addition of T1D GRS to the
currently established predictors (i.e., age,
autoantibody number, DPT-1 Risk Score)
can best add predictive power and as-
sist in stratification for prevention tri-
als. In the current study, multivariate
modeling of autoantibody status, DPT-1
Risk Score, age, and additional demo-
graphic factors still leaves the T1D GRS
as a significant independent predictor of
progression. This observation supports
the assessment of all of these features,
either in a combined model or a sequen-
tial approach, at entry to the TrialNet PTP
and other similar studies. Previous stud-
ies have shown conflicting results on the
ability of genetic factors, age, and auto-
antibody and metabolic data to predict
T1D (36,37). Some of the differences in
the role of genetics could be due to the
challenges of capturing genetic informa-
tion; an advantage of the T1D GRS is that
it includes SNPs tagging other significant
HLA risk alleles, e.g., HLA DRB1*15,
DRB1*57, and A24, in addition to non-
HLA SNPs. Supporting this notion, in the
current study, the T1D GRS was superior
to HLA DR3/DR4-DQ8 alone for predict-
ing progression to T1D. Because the T1D
GRS further stratified T1D risk beyond
that associated with autoantibody num-
ber in individuals with low DPT-1 Risk
Score, it is plausible that applying the
T1D GRS earlier in life would allow dis-
crimination of the individuals who will
develop a high DPT-1 Risk Score and
T1D.
The unique longitudinal follow-up and
monitoring of the TrialNet PTP study
also allowed us to further investigate
the contribution of the GRS to preclinical
stages of T1D. Progression from single
to multiple autoantibody positivity was
independently predicted by the T1D GRS
only in participants ,35 years of age,
who have higher risk of progression, al-
though the number of individuals $35
years old in the analysis was relatively
limited and thus we cannot conclusively
rule out the influence of the GRS in the
subset of individuals $35 years old. We
had previously observed the protective
effect of age on progression to T1D in at-
risk adults with a threshold of 35 years of
age (38) and the influence of age on the
effect of another genetic factor, namely,
type 2 diabetes–associated TCF7L2 variants
on T1D progression (39). Interestingly, de-
spite having been originally discovered in
studies of childhood diabetes, the T1D GRS
was able to identify more adult than child-
hood T1D cases in a recent study of T1D
in UK Biobank (40). These results and
those from the current study suggest that
the genetic factors that regulate the pro-
gression of islet autoimmunity may slightly
differ by age and further support the
emerging notion that age is a key factor
in the heterogeneity of T1D pathogen-
esis. The importance of age in progres-
sion through T1D stages is also highlighted
by its significant and strong influence in
the multivariable models even after ad-
justment for DPT-1 Risk Score, which in-
cludes age as well.
We tested the predictive power of a
restricted set of the top 10 SNPs fromour
score (14), which proved to contain the
vast majority of predictive power in the
T1D GRS. This is unsurprising owing to
the high weights of HLA and the top SNPs
in the score. These results may be rel-
evant to large-scale studies where the
cost of the T1D GRS per individual may
be important.
The study limitations include that it
evaluated the performance of T1D GRS
only in autoantibody-positive relatives of
people with T1D, although recent data
(32) suggest that the T1D GRS will be a
significant predictor in general popula-
tion cohorts as well. We tested the T1D
GRS and derived score cutoffs within the
1,244 TrialNet PTP participants who had
ImmunoChip data; we anticipate that
expanding SNP analysis to the whole
cohort will validate the current findings.
Similarly, TrialNet is a cohort of .80%
non-Hispanic whites and, although we
were able to control for race/ethnicity,
the T1D GRS needs to be specifically
tested in other races and possibly mod-
ified according to genetic differences.
Finally, it is possible that newly dis-
covered variants, better capture of
known HLA variants, stage-specific var-
iants (e.g., progression from single to
multiple autoantibody positivity), or
longer follow-up of the cohort (allow-
ing us to assess whether the rate of
progression and its factors change with
time) could improve understanding of
the long-term predictive power of the
T1D GRS.
In summary, the T1D GRS is a strong
independent predictor of progression of
islet autoimmunity and to clinical T1D
in the TrialNet PTP study. Multivariate
modeling suggests that the combina-
tion of islet autoantibody measure-
ments, DPT-1 Risk Score, age, and T1D
GRS into a prediction model may im-
prove assessment of T1D risk. This study,
in addition to recent positive analyses
in BABYDIAB (29), the Diabetes Autoim-
munity Study in the Young (DAISY) (31),
and TEDDY (32), suggest that future T1D
prediction studies are likely to use a
genetic score, such as the T1D GRS, at
enrollment. These findings warrant fur-
ther investigations on the use of the T1D
GRS for early assessment of T1D risk,
particularly in longitudinal studies.
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